

For Health Professionals Who Care for People with Cancer

Inside This Issue

Editor's Choice: New Programs

BRAJPNCT: Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab

BRLACPNAC: Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide

BRLACPNACG: Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide

BRLAPNAC: Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide

BRLAPNACG: Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide

Provincial Systemic Therapy Policies

III-200 Remote Ordering of Systemic Therapy during COVID-19 Pandemic, III-40 Systemic Therapy Treatments, III-130 Accessing Non-Benefit Cancer Drugs, III-50 Intrathecal Labelling Procedure

Cancer Drug Manual®

Revised Docetaxel, Pamidronate, Pemetrexed | CDM Editorial Board Changes | Acknowledgment of CDM Editorial Board and Expert Reviewers

BC Cancer Benefit Drug List

New BRAJPNCT, BRLACPNAC, BRLACPNACG, BRLAPNAC, BRLAPNACG

New Protocols, PPPOs and Patient Handouts

BR BRAJPNCT, BRLACPNAC, BRLACPNACG, BRLAPNAC, BRLAPNACG

Revised Protocols, PPPOs and Patient Handouts

BR BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJFCD, BRAJFCDT, BRAJTDC, BRAJTTW, BRLAACD, BRLAACDT, BRLATACG, BRLATWAC, BRLACTWAC, BRLACTWACG, BRAJDCARBT, BRAVGEMP, BRAVPAM | **GU** GUPAZO, GUPLHRH, GUPLHRHA, GUPNSAA | **LY** LYBRENTUX, LYCTCLBV | **SC** SCPAINLI

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment program effective 1 January 2023. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Breast

Paclitaxel NAB as Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer (BRAJPNCT, BRLACPNAC, BRLACPNACG, BRLAPNAC, BRLAPNACG) — The BC Cancer Breast Tumour Group is implementing several more paclitaxel NAB protocols in the neoadjuvant or adjuvant setting for patients with previous severe hypersensitivity reaction (HSR) or anaphylaxis to paclitaxel or docetaxel that is not manageable despite using premedications. This is a continuation of the implementation started in October 2022 (please refer to this issue of Systemic Therapy for more details).

Editor's Choice

New Programs

Patients with previous moderate HSR that cannot be managed with premedications due to a strong contraindication to high-dose steroids may also receive paclitaxel NAB. Although premedication with steroid, antihistamine and H2-receptor antagonist is not required with paclitaxel NAB, dexamethasone may still be needed as antiemetics for other concurrent agents (e.g., carboplatin). Paclitaxel NAB is repeated 3-weekly to complete the total number of cycles in the original paclitaxel or docetaxel protocol.

Clinicians are reminded to thoroughly review previous treatment exposure due to likelihood of mismatching the cycle vs. the actual dose number for affected regimens.

Provincial Systemic Therapy Policies

PRACTICE CHANGES:

III-200 Remote Ordering of Systemic Therapy during COVID-19 Pandemic: Effective 1 January 2023, physicians will be required to destroy the original pre-printed orders (PPOs) and they no longer need to bring the original PPOs to their regional centre. An Information Bulletin will also be shared widely through the regional and medical leadership.

DOCUMENT AMALGAMATIONS :

III-40 Systemic Therapy Treatments: Information from the III-130 Policy (see below) has been incorporated into the III-40 Policy.

III-130 Accessing Non-Benefit Cancer Drugs: This policy is archived effective 1 Jan 2023 as the information has been incorporate into the III-40 Policy (see above).

III-50 Intrathecal Labelling Procedure: The intrathecal policy and procedure have been combined into a single procedure document.

OTHER UPDATES:

High Alert Medications: This policy has been updated with the followings:

- Updated links
- Moved appendices from BC Cancer website location to policy document
- Appendix E: Calcium chloride 10 %-- Removed "Emergency Cart (Abbotsford): Supplied by Abbotsford Regional Hospital"
- Appendix F: Added alteplase IV to automatic dispensing cabinet IDC alert

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

Revised Documents

Docetaxel Patient Handout

Side Effects: revised acetaminophen dosing information in *Nail Changes* to include max daily dose; updated *nausea/vomiting* and *diarrhea* to include new messaging about dehydration; updated *numbness and tingling* to include new management for peripheral neuropathy; updated template wording throughout

Pamidronate Monograph

Supply and Storage: added current brands and deleted outdated information

Parenteral Administration table: updated Intermittent Infusion to include information about 1 h infusions in patients with renal failure (to align with current practice in protocols)

Dosage Guidelines: updated dosage in renal and hepatic failure

Pemetrexed Chemotherapy Preparation and Stability Chart

Vial stability: updated to include room temperature storage

Product stability: updated to include room temperature storage

On behalf of the Cancer Drug Manual writing team, I would like to acknowledge the many contributions of the CDM Editorial Review Board and our expert reviewers for the year 2022. Thank you all for your ongoing support of the CDM and for generously sharing your time and expertise throughout the year.

Editorial Board

Physicians

Angela Chan, BC Cancer - Surrey
Mario Ho, BC Cancer - Prince George
Jean-Michel Lavoie, BC Cancer - Victoria

Nurses

Megan Crosby, BC Cancer- Prince George, Provincial Professional Practice Nursing
Michelle LaFreniere, BC Cancer – Victoria, Provincial Professional Practice Nursing

Pharmacists

Alysha Bharmal, BC Cancer - Surrey
Anne Dar Santos, BC Cancer - Provincial Pharmacy
Jennifer Kendrick, BC Children's Hospital
Khushminder Rai, BC Cancer - Surrey
Jennifer Suess, BC Cancer - Abbotsford

Expert Reviewers

Physicians

Vanessa Bernstein, BC Cancer – Victoria
Stephen Chia, BC Cancer - Vancouver
Linda Foltz, BC Cancer - Vancouver
Alina Gerrie, BC Cancer - Vancouver
Ursula Lee, BC Cancer - Surrey
Tom Nevill, BC Cancer - Vancouver
David Sanford, BC Cancer - Vancouver
Alannah Smrke, BC Cancer - Vancouver
Kevin Song, BC Cancer - Vancouver

Nurses

Megan Crosby, BC Cancer - Prince George, Provincial Professional Practice Nursing
Michelle LaFreniere, BC Cancer – Victoria, Provincial Professional Practice Nursing

Pharmacists

Winnie Cheng, BC Cancer, BC Cancer - Provincial Pharmacy
Megan Darbyshire, BC Cancer - Provincial Pharmacy

Cancer Drug Manual[©]

Jennifer Kendrick, BC Children's Hospital
Katherine Lalaria, Vancouver General Hospital
Carmen Mountford, Vancouver General Hospital
Tanya Leduc, BC Cancer - Victoria
Louisa Pang, BC Cancer - Vancouver
Khushminder Rai, BC Cancer - Surrey
Robert Tillmanns, BC Cancer - Abbotsford

Other

Devon Poznanski, BC Cancer - Vancouver (Provincial Patient and Family Education)

BC Cancer Benefit Drug List

New Programs

The following treatment programs have been added to the [Benefit Drug List](#) effective 01 January 2023:

Protocol Title	Protocol Code	Benefit Status
Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE) , CARBOplatin and Trastuzumab	BRAJPNCT	Class I
Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNAC	Class I
Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNACG	Class I
Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNAC	Class I
Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNACG	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
BRLACPNAC	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
BRLACPNACG	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
BRLAPNAC	Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB followed by DOXOrubicin and Cyclophosphamide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
BRLAPNACG	Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB followed by DOXOrubicin and Cyclophosphamide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJACT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel	<i>Precautions updated</i>	-	-
BRAJACTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel	<i>Precautions updated</i>	-	-
BRAJACTT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab	<i>Precautions updated</i>	-	-

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJACTTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab	<i>Precautions updated</i>	-	-
BRAJACTW	Neoadjuvant or Adjuvant Therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide followed by Weekly PACLitaxel	<i>Precautions updated</i>	-	-
BRAJDCARBT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab	<i>premedications and precautions updated</i>	<i>premedications updated</i>	-
BRAJFCD	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and DOCEtaxel	<i>Precautions updated</i>	-	-
BRAJFCDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab	<i>Precautions updated</i>	-	-
BRAJTDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Trastuzumab, DOCEtaxel and Cyclophosphamide	<i>Precautions updated</i>	-	-
BRAJTTW	Adjuvant Therapy for Breast Cancer using Weekly PACLitaxel and Trastuzumab	<i>Precautions updated</i>	-	-
BRAVGEMP	Palliative Therapy for Metastatic Breast Cancer using CISplatin and Gemcitabine	<i>premedications updated</i>	<i>premedications updated</i>	-
BRAVPAM	Prevention of Skeletal Related Events Secondary to Breast Cancer Metastases Using Pamidronate	<i>Tests revised</i>	<i>Prechemo metrics removed</i>	-
BRLAACD	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide followed by DOCEtaxel	<i>Precautions updated</i>	-	-
BRLAACDT	Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab	<i>Precautions updated</i>	-	-
BRLACTWAC	NEOAdjuvant Therapy for Triple Negative Breast Cancer Using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>premedications and precautions updated</i>	<i>premedications updated</i>	-
BRLACTWACG	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>premedications and precautions updated</i>	<i>premedications updated</i>	-
BRLATACG	NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel followed by DOXOrubicin and Cyclophosphamide	<i>precautions updated</i>	-	-

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRLATWAC	NEOAdjuvant Therapy for Locally Advanced Breast Cancer using Weekly PACLitaxel followed by DOXOrubicin and Cyclophosphamide	<i>precautions updated</i>	-	-
GU Genitourinary				
GUPAZO	Palliative Therapy for Renal Cell Carcinoma Using PAZOpanib	<i>eligibility updated</i>	-	-
GUPLHRH	Therapy for Prostate Cancer using LHRH Agonist (Goserelin, Leuprolide or Buserelin)	<i>eligibility updated, tests added</i>	<i>tests updated (pending TG approval)</i>	-
GUPLHRHA	Therapy for Advanced Prostate Cancer Using LHRH Antagonist Degarelix	<i>institution name updated, tests added</i>	<i>institution name and tests updated</i>	-
GUPNSAA	Non-Steroidal Treatment of Prostate Cancer	<i>eligibility, tests, precautions, and contact updated</i>	<i>tests updated</i>	-
LY Lymphoma				
LYBRENTUX	Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin	<i>eligibility, exclusions and contact updated</i>	-	-
LYCTCLBV	Treatment of Cutaneous T-Cell Lymphoma (CTCL) with Brentuximab Vedotin	<i>eligibility revised</i>	-	-
SC Supportive Care				
SCPAINLI	Extreme Pain Therapy Using Parenteral Lidocaine	<i>dosing clarified, maximum dose removed</i>	-	-

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
CST Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/cst-bulletin		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Manufacturer Patient Assistance Programs: http://www.bccancer.bc.ca/mpap		
Library/Cancer Information	604-675-8003	requests@bccancer.bc.ca toll free 888-675-8001 x 8003
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCcancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
 Fatima Ladha, BScPharm, PharmD (Assistant Editor)
 Mario de Lemos, PharmD, MSc(Oncol)
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
 Samuel Hackett, RN, BScN, CON(C)
 Alison Pow, BScPharm